With second FDA approval, the transformative power of CAR-T is multiplied – Penn: Office of University Communications
Penn: Office of University Communications |
With second FDA approval, the transformative power of CAR–T is multiplied
Penn: Office of University Communications The technology behind Kymriah originated at Penn from the innovative work led by Penn Medicine’s Carl June in developing the CAR-T platform for reprogramming T cells. An initial cohort of patients was treated with the CAR–T cell therapy at Penn, with … |
Penn State News |
Cocoa CRISPR: Gene editing shows promise for improving the ‘chocolate tree’
Penn State News UNIVERSITY PARK, Pa. — Use of the powerful gene-editing tool CRISPR-Cas9 could help to breed cacao trees that exhibit desirable traits such as enhanced resistance to diseases, according to Penn State plant scientists. The cacao tree, which grows in … |
|
Vail’s first patrol dog Henry undergoes stem cell therapy in Gypsum
Vail Daily News On Monday, May 7, Henry added to his legacy, becoming the third dog to receive stem cell therapy from Gypsum Animal Hospital. “It is an extremely safe, effective, natural, FDA-approved therapy,” said Stephen Sheldon, DVM, of Gypsum Animal Hospital … |
|
What’s next for CAR–T cell therapy at Penn
Philadelphia Business Journal Last week, Novartis received its second approval for Kymriah, a CAR–T cell therapy developed by researchers at Penn Medicine and Children’s Hospital of Philadelphia. The therapy, which involves bioengineering a patient’s own cells to boost their … |
|
Crowdfunding Exaggerates Efficacy of Unproven Stem Cell Tx
Monthly Prescribing Reference HealthDay News — Crowdfunding campaigns for unproven stem cell-based interventions tend to exaggerate the efficacy and underemphasize the risks, according to a research letter published in the May 8 issue of the Journal of the American Medical … Study: Crowdfunding campaigns for stem cell treatments ‘potentially misleading’Becker’s Hospital Review |